A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee

Osteoarthritis and Cartilage

Volumn 14, Issue 2, 2006, Pages 154-162

  Kirchner, M ^a   Marshall, Dennis ^b  

^a Nova Clinic   (Germany)

^b Ferring Pharmaceuticals Inc   (United States)

Author keywords

Hyaluronan; Osteoarthritis; Viscosupplementation

Indexed keywords

EUFLEXXA; HYALURONIC ACID; HYALURONIC ACID DERIVATIVE; PARACETAMOL;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BIOENGINEERING; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS LINKING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FERMENTATION; FOLLOW UP; HUMAN; JOINT EFFUSION; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; MULTICENTER STUDY; PAIN ASSESSMENT; PATIENT SATISFACTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADJUVANTS, IMMUNOLOGIC; AGED; ANALYSIS OF VARIANCE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYALURONIC ACID; MALE; MIDDLE AGED; MOLECULAR WEIGHT; OSTEOARTHRITIS, KNEE; PAIN; PROTEIN ISOFORMS; RANGE OF MOTION, ARTICULAR; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 30544442655     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2005.09.003     Document Type: Article

References (37)

1. E.A. Balazs The physical properties of synovial fluid and the special role of hyaluronic acid A.J. Helfet Disorders of the Knee 1974 Lippincott Philadelphia 63-75
2. R. Day P. Brooks P.G. Conaghan M. Petersen A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee J Rheumatol 31 2004 775-782
3. C.T. Wang J. Lin C.J. Chang Y.T. Lin S.M. Hou Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials J Bone Joint Surg Am 86-A 2004 538-545
4. R.D. Altman R. Moskowitz A randomized clinical trial of intra-articular sodium hyaluronate in patients with osteoarthritis of the knee: A summary Am J Orthop 28 Suppl 11 1999 3-4
5. M. Wobig A. Dickhut R. Maier G. Vetter Viscosupplementation with hylan G-F 20: A 26-week controlled trial of efficacy and safety in the osteoarthritic knee Clin Ther 20 1998 410-423
6. E. Maheu X. Ayral M. Dougados A hyaluronan preparation (500-730 kDa) in the treatment of osteoarthritis: A review of clinical trials with Hyalgan Int J Clin Pract 56 2002 804-813
7. J.P. Raynauld G.W. Torrance P.A. Band C.H. Goldsmith P. Tugwell V. Walker et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 1 of 2): Clinical results Osteoarthritis Cartilage 10 2002 506-517
8. A. Lussier A.A. Cividino C.A. McFarlane W.P. Olszynski W.J. Potashner R. De Medicis Viscosupplementation with hylan for the treatment of osteoarthritis: Findings from clinical practice in Canada J Rheumatol 23 1996 1579-1585
9. E.A. Balazs J.L. Denlinger Viscosupplementation: A new concept in the treatment of osteoarthritis J Rheumatol Suppl 39 1993 3-9
10. A. Gomis M. Pawlak E.A. Balazs R.F. Schmidt C. Belmonte Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents Arthritis Rheum 50 2004 314-326
11. C. Weiss P.A. Band Basic principles underlying the development of viscosupplementation for the treatment of osteoarthritis J Clin Rheumatol 3 1999 S2-S11
12. Hyalgan® [package insert]. Washington, DC: Fidia Pharmaceutical Corporation 2001.
13. Supartz® [package insert]. Memphis, TN: Smith & Nephew 2001.
14. Synvisc® [package insert]. Ridgefield, NJ: Biomatrix Inc. 2003.
15. V.M. Goldberg R.D. Coutts Pseudoseptic reactions to hylan viscosupplementation: Diagnosis and treatment Clin Orthop 419 Feb 2004 130-137
16. S. Pullman-Mooar P. Mooar M. Sieck G. Clayburne H.R. Schumacher Are there distinctive inflammatory flares after hylan g-f 20 intraarticular injections? J Rheumatol 29 2002 2611-2614
17. S.S. Leopold W.J. Warme P.D. Pettis S. Shott Increased frequency of acute local reaction to intra-articular hylan GF-20 (synvisc) in patients receiving more than one course of treatment J Bone Joint Surg Am 84-A 2002 1619-1623
18. A.L. Chen P. Desai E.M. Adler P.E. Di Cesare Granulomatous inflammation after Hylan G-F 20 viscosupplementation of the knee: A report of six cases J Bone Joint Surg Am 84-A 2002 1142-1147
19. I.M. Zardawi I. Chan Synvisc perisynovitis Pathology 33 2001 519-520
20. Balazs EA. Ultrapure hyaluronic acid and use thereof. US Patent No. 4,141,973. 1979.
21. Nimrod A, Greenman B, Landsberg M, Beck Y. Bio-Technology General Corp. Method of producing high molecular weight sodium hyaluronate by fermentation of Streptococcus. US Patent No. 4,780,414. Oct. 25, 1988.
22. Nimrod A, Greenman B, Kanner D, Landsberg M. Bio-Technology General Corp. High molecular weight sodium hyaluronate. US Patent No. 4,784,990. Nov. 15, 1988.
23. E. Tamir D. Robinson R. Koren G. Agar N. Halperin Intra-articular hyaluronan injections for the treatment of osteoarthritis of the knee: A randomized, double blind, placebo controlled study Clin Exp Rheumatol 19 3 2001 265-270
24. G.H. Lo M. LaValley T. McAlindon D.T. Felson Intra-articular hyaluronic acid in treatment of knee osteoarthritis: A meta-analysis JAMA 290 23 2003 3115-3121
25. N. Bellamy J. Campbell V. Robinson T. Gee R. Bourne G. Wells Viscosupplementation for the treatment of osteoarthritis of the knee Cochrane Database Syst Rev 18 2 Apr 2005 CD005321
26. H.R. Schumacher Jr. Aspiration and injection therapies for joints Arthritis Rheum 49 3 2003 413-420
27. J.H. Kellgren J.S. Lawrence Radiological assessment of osteo-arthrosis Ann Rheum Dis 16 1957 494-502
28. N. Bellamy W.W. Buchanan C.H. Goldsmith J. Campbell L.W. Stitt Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in subjects with osteoarthritis of the hip or knee J Rheumatol 15 1988 1833-1847
29. T. Pham H.D. van der M. Lassere R.D. Altman J.J. Anderson N. Bellamy et al. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria J Rheumatol 30 2003 1648-1654
30. R. Altman K. Brandt M. Hochberg R. Moskowitz N. Bellamy D.A. Bloch et al. Design and conduct of clinical trials in patients with osteoarthritis: Recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop Osteoarthritis Cartilage 4 1996 217-243
31. E.W. Ehrich G.M. Davies D.J. Watson J.A. Bolognese B.C. Seidenberg N. Bellamy Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis J Rheum 27 2000 2635-2641
32. N. Bellamy Osteoarthritis N. Bellamy Musculoskeletal Clinical Metrology 1993 Kluwer Academic Publishers The Netherlands 169-176
33. M.E. Adams M.H. Atkinson A.J. Lussier J.I. Schulz K.A. Siminovitch J.P. Wade et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: A Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone Osteoarthritis Cartilage 3 4 1995 213-225
34. N. Adam P. Ghosh Hyaluronan molecular weight and polydispersity in some commercial intra-articular injectable preparations and in synovial fluid Inflamm Res 50 2001 294-299
35. A.H. Morton P. Shannon Increased frequency of acute local reaction to intra-articular hylan G-F 20 (Synvisc) in subjects receiving more than one course of treatment (letter) J Bone Joint Surg 85A 2003 2050
36. M.M. Wolfe D.R. Lichtenstein G. Singh Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs N Engl J Med 340 1999 1888-1899
37. D.H. Solomon S. Schneeweiss R.J. Glynn Y. Kiyota R. Levin H. Mogun et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults Circulation 109 2004 2068-2073